Reimbursement for TREANDA

Cephalon Oncology is committed to supporting you through the reimbursement process. We provide you with convenient resources that make reimbursement easier to understand. These services are offered through a reimbursement support program called TREANDA Reimbursement Expertise.

To get personalized support when submitting reimbursement claims for TREANDA, you can contact the Hotline toll-free:

TREANDA Reimbursement Expertise Hotline
Phone: 1-888-5-TREANDA (1-888-587-3263)
Fax: 1-866-676-4073

TREANDA Reimbursement Expertise counselors are available by phone Monday through Friday, from 9 am to 8 pm Eastern Time. They can help with the following:

  • Benefit verification and coverage information
  • Policy benefit design
  • Pre-certifications/prior authorization support
  • Coverage guidelines and claim requirements
  • Personalized support through the claims process
  • Templates for letters of medical necessity
  • Appeal support
  • TREANDA Patient Assistance Program

When calling about patient-specific reimbursement issues, it may be necessary to have the following available:

  • Patient's name, address, and phone number
  • Date of birth
  • Social security number
  • Plan name
  • Plan policy number
  • Physician's name, address, and phone number
  • Date of service
  • Drug name
  • Dosing
  • Treatment schedule
  • Income level (if Paitent Assistance Applicant)

To initiate reimbursement support services, such as benefit investigations, prior authorizations, appeals support or patient assistance enrollment, please click below to download the updated Patient and Physician Enrollment Form. This form has been updated for greater ease of use.

Please call TREANDA Reimbursement Expertise (CORE) to assist you in completing the enrollment form or click above to download the form. Please mail or fax the form to:

Cephalon Oncology Reimbursement Expertise (CORE)
6900 College Blvd, Suite 1000
Overland Park, KS 66211
Fax: 1-866-676-4073

Cephalon does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

Click here to review the TREANDA Coding Guide for 2009.

TREANDA for Injection is indicated for treatment of patients with:

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established
  • Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen

The following serious adverse reactions have been associated with TREANDA in clinical trials: myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions, and other malignancies. Please see full Prescribing Information.